Skeletal muscle dysfunction affects about one-third of COPD patients and worsens clinical outcomes. While some treatments like androgens exist, effective clinical drugs are still lacking. This study highlights the potential role of GHK-cu, a peptide found in lower levels in COPD patients, in improving muscle function.
Many think of this peptide as having more beneficial effects on the skin, and wound healing, but this study found that in a mouse model, exogenous administration led to muscle retention, and that GHK-cu directly activates sirt1, a key regulator of muscle health, mitochondrial function, and oxidative defense.
1 Like
It certainly would be great to see some human clinical trials with GHK and/or GHK-Cu. I wonder if any are in the works?
1 Like
That would be great, I don’t know if the companies that have invested millions in myostatin inhibitors would be thrilled about them…
That’s pretty interesting. I’m going to have to give it a go 
GHK-cu is pretty reasonable cost wise. I’ve been using it for years in our skin care product. Many people use it SubQ in the Glow Protocol a peptide blend of three peptides: GHK-Cu, TB-500, and BPC-157
1 Like
Yeah, I’ve been looking into starting my own, based on the the Anela version, but still on the fence with the daily injections part. Getting there though! This new paper has me intrigued. I might do injections 3 times a week.
I’m also thinking of replacing one of the ingredients with kpv. I might have to play around, because it is said that bpc helps reduce the sting of ghk-cu, not sure if kpv does the same.
